Save
Email
Print
ShareFeb. 14, 2010 — A study published online on February 8 in the Journal of Experimental Medicine reports that several distinct mutations found in a subset of patients with acute myelogenous leukemia (AML) result in excess production of the same metabolite.
The enzyme isocitrate dehydrogenase 1 (IDH1), which normally facilitates production of the metabolite {alpha}-ketoglutarate, is mutated in approximately 80% of secondary brain tumors. This mutant version of IDH1 promotes excess production of a different metabolite: R (-)-2-hydroxyglutarate (2-HG).
A team led by Tak Mak (Toronto) detected elevated concentrations of 2-HG in the serum of the approximately 8% of AML patients with mutations in IDH1. In addition, they identified a mutation in IDH2 -- the sister enzyme of IDH1 -- in some AML patients. These patients also had unusually high serum levels of 2-HG.
Additional work is needed to understand if and how 2-HG influences brain cancer and/or leukemia progression. However, as these mutations have so far only been found in cancer, they may prove useful as drug targets.
Reference: Gross, S., et al. 2010. J. Exp. Med. doi:10.1084/jem.20092506.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by Rockefeller University Press, via EurekAlert!, a service of AAAS.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
more 
